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 Abstract  
Objective: The objective of this selective EBM review is to determine whether or not Platelet 
Rich Plasma is efficacious in regrowth of hair in both androgenic alopecia and alopecia areata.  
Study Design: Review of two blinded randomized controlled trials and one prospective cohort 
study. Populations studied were Adults over 18 with hair loss. All articles published in peer-
reviewed journals in English.  
Data Source: 3 articles found via PubMed and NCBI 
Outcomes Measured: One prospective cohort study, and two randomized control trials evaluating 
hair regrowth after PRP scalp injections. Outcomes were reported by patient satisfaction, mean 
hair increase and hair regrowth in hair loss areas.   
Results: Gentile (2015) enrolled 23 patients with androgenic alopecia, with 3 withdrawals. After 
PRP injection a mean increase in total hair density of 45.9 hairs per cm2 compared with baseline 
was observed at 3 months. Ginki (2014) enrolled 22 volunteers with androgenic alopecia, with 2 
withdrawals. Hair densities were reported at monthly intervals with the highest reported at 4 
months: 170.70 plus or minus 37.81 hairs. Trink (2013) enrolled 45 patients with alopecia areata, 
with no withdrawals. 60 percent of the patients in the PRP group had complete remission of 
alopecia as compared to placebo. 
Conclusion: PRP injection for androgenetic alopecia and alopecia areata is a simple, safe and 
cost effective treatment for hair loss or thinning.  
Key words: Hair loss, PRP injection, platelet rich plasma, PRP and hair growth. 
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Introduction  
Androgenic alopecia (AGA) and alopecia areata (AA) are common hair loss disorders 
affecting adult populations worldwide. Alopecia areata is an autoimmune cause of hair loss and 
most common type in younger populations. Androgenic alopecia, also known as male pattern 
hair loss (MPHL) is the most common form of alopecia and affects up to 80% of white men and 
40% of women. 1 With such a strong prevalence, Physician Assistants in any field, certainly 
dermatology, can expect to council patents on alopecia throughout their careers.  
The etiology of male pattern hair loss is androgen-dependent, and a genetically 
determined trait. Dihydroxytestosterone (DHT) synthesized from testosterone by an enzyme 
called 5apha-reductase is thought to be the principal agent for MPHL.4 DHT binds preferentially 
to hair follicles, as compared to testosterone. Males with AGA have consistent higher levels of 
DHT and 5alpha-reducatase as compared to non-balding counterparts.4  
Female pattern hair loss (FPHL) (or female androgenetic alopecia) is believed to be the 
same entity.4 However, the requirement of androgens is less clear-cut than in men and the 
distribution of hair loss is generally different.4 In both men and women normal hair follicles 
follow a life cycle where the hair follicle undergoes a phase of rapid growth (anagen) to a resting 
period (telogen). In both men and women, AGA is characterized by an ongoing decline in the 
duration of anagen, and increase in the duration of telogen and miniaturization of scalp hair 
follicles.4  
Alopecia areata (AA) is a common autoimmune condition, causing inflammation induced 
hair loss. According to the National Alopecia Areata Foundation Over 6.6 million people in the 
United States and 147 million worldwide have or will develop alopecia areata at some point in 
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their lives. It is a common cause of abrupt-onset hair loss, with both sexes affected equally. 
Clinically presents with well-demarcated round or oval bald spots on the scalp or other parts of 
the body.4 Although it may occur at any age, alopecia areata is the most common form of 
alopecia seen in children. Currently no FDA approved treatment exists.3 
There is no exact number for health care visits or cost on health care system related to 
treating alopecia. With such a variability in treatment options and the cosmetic nature of the 
disease, figures reported are not consistent. Currently two FDA approved pharmaceuticals exist 
for androgenic alopecia: Topical Minoxidil and oral finasteride. Oral finasteride is a 5alpha-
reductase inhibiter which prevents conversion of testosterone to DHT. The side effect profile 
includes decreases sex drive or ability.6 Minoxidil, a piperidinopyrimidine derivative, was noted 
to cause hypertrichosis when administered orally as an antihypertensive.4 It is now used as a 2% 
and a 5% topical treatment in a lotion or foam preparation.4 The mechanism of action is not fully 
understood. Clinical trials in only the vertex region of the scalp have shown regrowth in up 
30%–45% of patients. 4 Some patients experience an increased shedding in the first 4–6 weeks of 
application.4 Once started Minoxidil has to be taken indefinitely, with discontinuation any 
potential hair regrowth will return to baseline.  
Hair Restoration Surgery stands as the most definitive treatment. The most advanced 
method is Follicular Unit Transplant (FUE). With this procedure, hair follicles are extracted from 
the occipital and parietal region. Hair from this region is generally resistant to androgenic 
alopecia and placed in desired areas, usually from the frontal to crown regions. Hair transplant 
prices vary by region and clinic, but the range is typically from $2 to $10 per graft, with $4-5 per 
graft being the average.5 The total cost can range anywhere from $2,500 to $20,000.5 Transplant 
is classically permanent, however pattern hair loss of non- transplanted hair will continue. With 
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the invasive nature of the procedure and high cost there continues to be room for advancement in 
treatment of androgenic alopecia and alopecia areata.    
Platelet Rich Plasma (PRP) has emerged as a new treatment modality in regenerative 
plastic surgery and preliminary evidence suggests it might have a beneficial role in hair 
regrowth.. Platelet Rich Plasma is defined as an autologous concentration of plasma with a 
greater count of platelets than that of whole blood.2 Using the patient’s own blood, PRP is 
extracted. It’s action depends on the released growth factors from platelets. It has been 
investigated and used in numerous fields of medicine. Proponents of PRP technology suggest 
that its benefits include hard and soft tissue wound healing, and it is used in this manner in 
orthopedics, dermatology, maxillofacial surgery and plastic surgery.1, 2  PRP injection pricing 
varies by region with average price around 600-800 US Dollars per treatment.4  
Currently PRP is being investigated for hair regrowth with limited published data 
available. No published trials exists for using PRP in treatment alopecia areata. As a mechanism 
for hair growth Activated PRP seems to promote numerous growth factors. These include 
activation of transforming growth factor, platelet derived growth factor, vascular endothelial 
growth factor, epidermal growth factor and insulin like growth factor.1 It is proposed that these 
factors released from platelets act on the stem cells at the base of the follicle to promote growth 
and revascularization.2 This paper will evaluate these preliminary findings in both alopecia 
areata and androgenic alopecia.   
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Objective  
The objective of the selective EBM review is to determine whether or not Platelet Rich 
Plasma Injection is Efficacious in Treatment of Hair Loss in Androgenic Alopecia and Alopecia 
Areata? 
Methods  
In selecting the studies for this review, the author applied the following criteria. The 
enrolled populations had to be at least 18 years old with hair loss of non-traumatic etiology of 
either androgenic alopecia or alopecia areata. Inclusion: Adults over 18 year old with hair loss, 
Patient suitable for PRP injection from a surgical point of view. This entailed scalp free of any 
skin condition such as keloids, cellulitis, any break in skin integrity or hematologic pathology 
rendering scalp injection high risk. The alopecia areata group had to have recurrent disease of at 
least 2 years duration. Exclusion criteria: Any medical or drug related hair loss. Platelet disorder, 
thrombocytopenia, bone marrow aplasia, uncompensated diabetes, sepsis, cancer, 
antiaggregating therapy, systemic or topical treatment for male pattern hair loss in past 6 months 
for Gkini, and 12 months for Gentile. Topical drugs in exclusion criteria included Minoxidil, 
prostaglandin, analogs, retinoids, and corticosteroids. (Please see Table 1 for details of inclusion/ 
exclusion criteria and patient demographics)  
Table 1: Demographics and Characteristics of included studies 
Study  Type  #Pt
s  
Age 
(yrs) 
Inclusion Criteria  Exclusion Criteria  W/
D 
Inter
venti
ons  
 
Gentile1  
(2015) 
RCT 23 19-
63 
Age 19-63, male 
pattern hair loss 
Stage IIa-Stage IV 
according to the 
Norwood- 
Platelet disorder, 
thrombocytopenia 
antiaggregating therapy, 
systemic treatment for 
male pattern hair loss in 
3 PRP 
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Hamilton 
classification, 
suitable for PRP 
injection.  
past 12 months, bone 
marrow aplasia, 
uncompensated diabetes, 
sepsis, cancer, immune 
compromised and 
keloids.  
Gkini2 
(2014) 
Prospe
ctive 
Cohort 
Study 
22 24-
72 
Volunteers over 18 
years of age with 
diagnosed 
androgenic 
alopecia, Had not 
received any 
topical or systemic 
treatment for their 
hair loss during the 
last 6 months. 
Present history of 
immunosuppression 
(malignancy, 
chemotherapy, steroid 
therapy), dermatological 
disease affecting the 
scalp, autoimmune 
disorders, hematologic 
disorders, platelet 
dysfunction syndrome 
and on anticoagulation 
therapy, Aspirin or 
NSAIDs discontinued 
use 7 days before 
treatment/ Any other 
cause of hair loss.  
2 PRP 
Trink3 
(2013) 
RCT 45 >18 45 male and 
female otherwise 
healthy patients 
with chronic, 
recurring alopecia 
areata, of at least 2 
years duration. 
Having between 
four and 6 
symmetrically 
distributed patches 
of hair loss. 
Any medical conditions 
or other scalp or hair 
disease 
0 PRP 
 
 
Search Strategy 
All studies had to be published in peer reviewed journals in English, no earlier than 2013. 
The author searched the articles via PubMed, NCBI, and Medline. Key words: hair loss, PRP 
injection, PRP and hair growth, platelet rich plasma. Articles were selected based on relevancy 
and if they included patients oriented outcomes, i.e. (hair regrowth).  
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Outcomes Measured  
The intervention had to be PRP scalp injection using patients own blood with the 
outcomes measured being hair regrowth and mean hair increase. The three articles evaluated 
include one prospective cohort study, and two randomized control trials evaluating hair regrowth 
after PRP scalp injections. The prospective study by Trink had no comparison groups, all 
patients were injected treated with PRP and followed for hair regrowth. The RCT by Gentile and 
Gkini included a placebo and treatment group. Statistics reported or used: RRR, ARR, NNT, and 
P-values. How are they measured: Dermoscopic evaluation of scalp for Hair regrowth in bald 
spots, Patient satisfaction, Mean +/- standard deviation of hairs, mean hair increase. 
Results  
In all studies PRP was obtained by peripheral venous access, withdrawing and 
centrifuging patients’ blood. Interfollicular injection of PRP was performed by experienced 
Physicians in each of the studies. In the study by Gentile, 23 patients were enrolled with 3 that 
withdrew and were not included in statistical analysis. Outcomes were measured by mean hair 
increase after PRP injection. All patients were evaluated at beginning of study, 2months, 6, 12, 
16 and 24 months. The results of this study showed a significant increase in the mean hair count 
for the treatment area after 3 months (3 months vs. 0 month), with a mean increase of 33.6 hairs 
in the target area compared with baseline, while the control area showed a mean decrease of 3.2 
hairs (control vs. treatment: p , .0001). Accordingly, in the treatment area, a mean increase in 
total hair density of 45.9 hairs per cm2 compared with baseline was observed after 3 months, and 
the control area displayed a mean decrease of 3.8 hairs per cm2) in hair density at the same time 
(control vs. treatment: p,.0001). In addition, terminal hair density improved significantly by 40.1 
hairs per cm2 in the treatment area compared with baseline, while it decreased by 5.6 hairs per 
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cm2 in the control area of the scalp (control vs. treatment: p = .0003). There were no statistically 
significant differences in villus hair density between the study and the control area after 3 
months. 
In the Study by Ginki, 22 volunteers (20 men, 2 women) with androgenic alopecia were 
enrolled. Of the 22 patients enrolled, 2 withdrew and were not included in statistical analysis. 
The outcomes were measured by satisfaction questioner and mean hair increase. Hair regrowth 
satisfaction surveys reported a high satisfaction rate of 7.1 on a 1-10 scale. 85% of Patients of 
patients reported an improvement in hair quality and thickness. 65% of patients reported an 
increase in hair density. 
Additionally mean Hair densities were reported at many time intervals of treatment. All 
tests were two tailed with P values less than .05. Time intervals were in months. Hair density 
(hair/cm2) significantly increased at T3 (154.80 ± 34.39), at T4 (170.70 ± 37.81) at T5 (156.23 ± 
37.75) and at T6 (153.70 ± 39.92) (P < 0.001) compared to the onset of therapy (T1). The highest 
hair density recorded was at T4 (4 months post PRP injection).2 The percent increase rate from 
baseline (T1) was 0.45%, 8.18%, 19.9%, 9.19% and 7.41% at T2, T3, T4, T5 and at T6, 
respectively.2 Regarding failure rate none of the patients presented decreased hair density 
compared to that of baseline. One patient reported no change in hair density or growth at T3 and 
T4. At T5 (5 months past treatment) one patient a decrease of 1 hair/cm2 in hair density 
comparing to that of T1. And at T6 30% of patients presented a mean decrease of 2 hair/cm2.  
Trink enrolled 45 patients with alopecia areata (20 men, 25 women, mean age 28 years). 
No patients were excluded from the study. Patient were randomized and 15 patients received 
placebo, 15 received PRP injection and 15 received a TrA (triamcinolone acetonide) which is a 
treatment option for alopecia areata not approved by the FDA. Outcomes were measured by 
Stanczak, PRP Injection for Alopecia 8 
 
dermoscopic evaluation of scalp for Hair regrowth in alopecia areata bald spots. PRP Platelet 
Rich Plasma was found to increase hair growth significantly and to decrease hair dystrophy as 
compared to placebo. 60 percent of the patients in the PRP group had complete remission of 
alopecia as compared to placebo. A numbers needed to treat (NNT) analysis shows that a PA 
would need to treat 3 patients with platelet rich plasma to prevent 1 patient from having 
continued bald spots, compared with control.   
Safety: Patients own blood was used for all three PRP injection studies. No adverse reactions or 
events were reported. Lidocaine was used to anesthetize the scalp so the procedure was very 
tolerable. 
Discussion 
 Androgenic Alopecia remains the most common hair disorder without satisfactory 
treatment. Due to the shortened anagen phase and diminishing hair follicle, characteristic of AA, 
current therapeutic therapies target proliferation during the hair cycle. Numerous products have 
been proposed with only minoxidil and finasteride approved by the FDA. Minoxidil prolongs 
anagen phase and increases hair follicle size.2 Finasteride has been shown to reduce pattern hair 
loss associated with increased expression of caspases and apoptosis related androgen.2 However, 
these medications have their limitations in efficacy, compliance, and patient satisfaction. 
Additionally a variety of both topical and systemic side effects exist, with erectile dysfunction as 
an example. Hair transplant is currently the most definitive option but comes with a high cost, 
downtime from work and dependence on donor area for hair grafts. The search continues for new 
treatment option for alopecia.  
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Presently PRP is being investigated for hair regrowth with limited published data 
available. Alopecia areata is an autoimmune cause of hair loss, without any FDA approved 
treatment modality. Furthermore, no published trials exist for using PRP in treatment of alopecia 
areata. As a mechanism for hair growth Activated PRP seems to promote numerous growth 
factors. PRP induced activation of antiapoptotic regulators such as Bcl-2 protein and Akt-
signaling, which prolongs survival of dermal papilla cells during the hair cycle.2 This activation 
also includes transforming growth factor, platelet derived growth factor, vascular endothelial 
growth factor, epidermal growth factor and insulin like growth factor.1 It is proposed that these 
factors released from platelets act on the stem cells at the base of the follicle to promote growth 
and revascularization, prolonging the anagen phase of the hair cycle.2 
In summary, Gentile (2015) enrolled 23 patients with androgenic alopecia, with 3 
withdrawals. After PRP injection a mean increase in total hair density of 45.9 hairs per cm2 
compared with baseline was observed at 3 months. Ginki (2014) enrolled 22 volunteers with 
androgenic alopecia, with 2 withdrawals. Hair densities were reported at monthly intervals with 
the highest reported at 4 months: 170.70 plus or minus 37.81 hairs. Trink (2013) enrolled 45 
patients with alopecia areata, with no withdrawals. 60 percent of the patients in the PRP group 
had complete remission of alopecia as compared to placebo. With these combined results it is 
clear that Platelet Rich plasma is efficacious treatment for both androgenic alopecia and alopecia 
areata.  
Some sources error might include lack of common reference protocol for PPR 
preparation and injection. For example, volumes of PRP injected varied between studies or was 
not specified. Different brands of equipment were used with different physicians injecting the 
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scalp. Time intervals of injection and frequency also varied. The degree of hair loss also varied 
between patients, although this would be a nearly impossible variable to control.   
Conclusion 
PRP injection for androgenetic alopecia and alopecia areata is a simple, safe and cost 
effective treatment for hair loss or thinning. The product is entirely from the patient’s own blood 
so any adverse effects are unlikely. The results showed reasonable improvement in hair loss, 
however far from complete resolution of alopecia. With only a handful of peer reviewed articles 
on PRP injection, clinical evidence is still weak. Future studies should incorporate a much larger 
sample size. I think it would also be beneficial for a board of PRP super-users to define an 
unequivocal reference protocol. This should including explicit placement instruction for PRP 
injection with set volume and details on increments into the scalp.  
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